Table 1. Appropriateness indicators of lung cancer management by HIRA of Korea.
| Category | Area | Evaluation index |
|---|---|---|
| Structure (1) | Treatment ability | 1. Organization of lung cancer specialists |
| Process (19) | Diagnostic assessment and completeness of medical records (5) | 2. Records of smoking history |
| 3. Records of performance status | ||
| 4. Detailed examination before treatment | ||
| 5. Records of cancer stage by clinicians | ||
| 6. Pathologic confirmation before treatment | ||
| Surgery (2) | 7. Completeness of pathology report | |
| 8. Dissection or sampling of lymph nodes | ||
| Systemic treatment (8) | 9. Consent before chemotherapy | |
| 10. Use of flow sheet | ||
| 11. No chemotherapy in stage IA NSCLC patients | ||
| 12. Adjuvant chemotherapy within 8 weeks after surgery | ||
| 13. Use of antiemetics | ||
| 14. CCRT in LD-SCLC | ||
| 15. Assessment of AEs | ||
| 16. Periodic tumor response evaluation during chemotherapy in patients with stage IIIB/IV NSCLC | ||
| Radiotherapy (4) | 17. Records for radiation therapeutic parameters | |
| 18. Recordings of AEs during definitive radiotherapy and electrical portal imaging | ||
| 19. Tumor response and evaluation of the AEs within 2 months after definitive radiotherapy | ||
| 20. The rate of CCRT in unresectable stage III NSCLC patients | ||
| Results (2) | 21. Mean hospital days | |
| 22. Mean cost during hospitalization days |
HIRA: Health Insurance Review and Assessment Service; NSCLC: non-small cell lung cancer; CCRT: chemotherapy combined with chemotherapy; LD: limited disease; SCLC: small cell lung cancer; AE: adverse events.